Brief: Portage Biotech Reports Updated Interim Data For Cancer Treatment
05/06/2023 14:41
June 5 (Reuters) - Portage Biotech Inc PRTG.O :
* PORTAGE BIOTECH REPORTS UPDATED INTERIM DATA FOR LEAD INKT
ENGAGER, PORT-2, IN A PHASE 1/2 TRIAL FOR THE TREATMENT OF
ADVANCED MELANOMA AND METASTATIC NON-SMALL CELL LUNG CANCER AT
THE 2023 AMERICAN SOCIETY FOR CLINICAL ONCOLOGY (ASCO) ANNUAL
MEETING
* PORTAGE BIOTECH INC - INTERIM DATA PRESENTED AT ASCO SHOW
EARLY
EVIDENCE OF SINGLE AGENT ACTIVITY WITH MEANINGFUL REDUCTION OF
SEVERAL TARGET LESIONS
* PORTAGE BIOTECH INC - INTENDS TO EXPAND PHASE 1 PORTION OF
TRIAL
TO EVALUATE HIGHER DOSE LEVELS; WITH DATA ANTICIPATED BY END OF
2023
Source text for Eikon: ID:nGNXbxFXzM
Further company coverage: PRTG.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alpha Compute
See all newsBrief: Alpha Compute Corp. Provides Mid-Q2 2026 Update
Brief: Alpha Compute Ai Gpu Launch Update First Large-Scale Nvidia Blackwell Cluster
Brief: Alpha Compute Appoints Tom Richer To Advisory Board To Accelerate Ai Gpu Compute Infrastructure And Confidential Cloud Strategy
Brief: Alphaton Capital Rebrands As Alpha Compute Corp. To Reflect Its Growing Ai Compute Business
Brief: Alphaton Capital Announces $43 Million Ai Infrastructure And Financing Partnership With Vertical Data